Switch Language

Brand Navigation Banner DE

76 years, Metastatic NSCLC adenocarcinoma

33 years, Papillary thyroid cancer

85 years, MSI-high colorectal cancer

PATIENT CASE

85 years, MSI-high colorectal cancer

Alt tag

Overview

Clinical presentation1

• Metastases in bowel and liver 

• Tumor was mismatch repair deficient (MLH1/PMS2), CIMP-high

 

Prior treatment1

• Pembrolizumab with progression after 3 months

 

TPM3–NTRK1 gene fusion detected

Treatment

Treatment with Larotrectinib 100 mg twice daily1

• Dose reduced to 50 mg after Grade 3
   elevation of liver function tests;
   re-escalation upon resolution
• Confirmed partial response* at 6 months
   with a maximum tumor reduction of 42%

 

Current status1

Partial response maintained, 
   and Larotrectinib treatment ongoing
   for 15 months

 

Baseline

Alt tag

End of cycle 4

Alt tag

* Investigator assessed according to RECIST. Images courtesy of Professor David Hong, MD Anderson Cancer Center. RECIST, Response Evaluation Criteria in Solid Tumors.

Larotrectinib is effective in TRK fusion GI cancer

Efficacy in TRK fusion GI cancer1

• N=14 patients (N=8 with colon cancer)

43% ORR all (95% CI 18-71)
  50% ORR colon (4 PR, 4 SD)

Median OS 33.4 months
  (95% CI 2.8-36.5)

 

Safety in TRK fusion GI cancer1

• Grade 3 or 4 AEs in 9 patients

• Treatment-related grade 3 AE in
  1 patient, no grade 4 TRAE

• No permanent discontinuations
  due to TRAE

 

Maximum change in tumor size (%)1

Alt tag

Based on data cut-off February, 2019; 
presented at ASCO-GI Annual Meeting 2020 

* 0% change from baseline. 

AE, adverse event; ORR, objective response rate; OS, overall survival; PR, partial response; SD, stable disease; TRAE, treatment-related adverse event

Fachinformation Vitrakvi®

Picture of the actual patient has been redacted. CIMP, CpG island methylator phenotype; MSI, microsatellite instability. 

References:

  • Berlin J, et al. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. J Clin Oncol 38, 2020 (suppl 4; abstr 824). Poster presentation at ASCO-GI on January 23, 2020. Return to content